Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual MeetingOral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated MilestonesRobust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care ConferenceBRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:50 a.m. EST.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on February 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough YearANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” JonesSeasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PST.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 MeetingOnly Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated MilestonesTopline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025
Annexon Biosciences to Present at the Jefferies London Healthcare ConferenceBRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 MeetingANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea Region Critical for Visual Acuity
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 13, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina CongressOnly Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted PortfolioBRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research.
Annexon Biosciences to Participate in Upcoming September Investor ConferencesBRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
